Adherence, patient preference and dosing frequency: Understanding the relationship

[en] Adherence to treatment among patients with chronic diseases is currently suboptimal. Poor adherence leads to reduced clinical benefit, a raised incidence of secondary complications and therefore increased healthcare costs. For patients with osteoporosis, long-term adherence to therapy is further complicated by the asymptomatic nature of the disease and the lack of options for patient self-monitoring. Bone densitometry and biochemical markers of bone turnover are assessments that could be used by physicians to provide feedback to patients on the effectiveness of medication. However, these feedback systems are costly and not readily available. Oral bisphosphonates are currently the first-line therapy for postmenopausal osteoporosis. However, they are associated with stringent dosing procedures, and some patients may experience upper gastrointestinal side-effects following administration. Alarmingly, approximately 50% of patients discontinue daily bisphosphonate therapy within 1 year, which negatively impacts upon treatment outcomes, leading to a reduced antifracture effect. Thus, there is a need for an effective therapy that enhances patient adherence. The impact of reducing bisphosphonate dosing frequency on therapeutic adherence has been documented in several studies. Data have shown that, although weekly dosing improves adherence compared with daily administration, levels are still suboptimal. Results from two recent studies that have assessed patient preference for a once-monthly compared with a weekly dosing schedule have demonstrated that patients prefer a monthly regimen (67-71%). Their reasons for preferring once-monthly dosing were that it would fit better with their lifestyle (49-77%) and would be more convenient (75%). A novel once-monthly bisphosphonate regimen, such as the ibandronate regimen, may therefore help patients to follow dosing guidelines and encourage them to stay on therapy longer, thereby improving overall therapy effectiveness.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Rabenda, Véronique ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

NEUPREZ, Audrey ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Language :

English

Title :

Adherence, patient preference and dosing frequency: Understanding the relationship

Publication date :

April 2006

Journal title :

BONE

ISSN :

8756-3282

eISSN :

1873-2763

Publisher :

Elsevier Science Inc, New York, United States - New York

Volume :

Issue :

4 Suppl 1

Pages :

S2-6

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 27 August 2009

Statistics

Number of views

80 (7 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

106

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

109

Bibliography

World Health Organization Prevention and management of osteoporosis World Health Organ. Tech. Rep. Ser. 921 2003 1 164
J.J. Caro, K.J. Ishak, K.F. Huybrechts, G. Raggio, and C. Naujoks The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos. Int. 15 2004 1003 1008
National Institutes of Health Osteoporosis prevention, diagnosis, and therapy NIH Consens. Statement 17 2000 1 36
A.N.A. Tosteson, M.R. Grove, C.S. Hammond, M.M. Moncur, G.T. Ray, and G.M. Hebert Early discontinuation of treatment for osteoporosis Am. J. Med. 115 2003 209 216
C. Lombas, C. Hakim, and J.R. Zanchetta Compliance with alendronate treatment in an osteoporosis clinic J. Bone Miner. Res. 15 Suppl. 1 2001 S529 [Abstract M406]
B. Ettinger, A. Pressman, and J. Schein Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis Am. J. Manag. Care 4 1998 1377 1382
B. Hamilton, K. McCoy, and H. Taggart Tolerability and compliance with risedronate in clinical practice Osteoporos. Int. 14 2003 259 262
C.S. Pickney, and J.A. Arnason Correlation between patient recall of bone densitometry results and subsequent treatment adherence Osteoporos Int. 16 2005 1156 1160
D.M. Black, S.R. Cummings, D.B. Karpf, J.A. Cauley, D.E. Thompson, and M.C. Nevitt Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1996 1535 1541
J. Reginster, H.W. Minne, O.H. Sorensen, M. Hooper, C. Roux, and M.L. Brandi Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos. Int. 11 2000 83 91
C.H. Chesnut III, A. Skag, C. Christiansen, R.R. Recker, J.A. Stakkestad, and A. Hoiseth Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J. Bone Miner. Res. 19 2004 1241 1249
S.R. Cummings, D.M. Black, D.E. Thompson, W.B. Applegate, E. Barrett-Conner, and T.A. Musliner Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 1998 2077 2082
P.D. Delmas, R.R. Recker, C.H. Chesnut, A. Skag, J.A. Stakkestad, and R. Emkey Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study Osteoporos. Int. 15 2004 792 798
J.P. Brown, D.L. Kendler, M.R. McClung, R.D. Emkey, J.D. Adachi, and M.A. Bolognese The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis Calcif. Tissue Int. 71 2002 103 111
M.R. McClung, R.D. Wasnich, R. Recker, J.A. Cauley, C.H. Chesnut, and K.E. Ensrud Oral daily ibandronate prevents bone loss in early postmenopausal women with osteoporosis J. Bone Miner. Res. 19 2004 11 18
T. Schnitzer, H.G. Bone, G. Crepaldi, S. Adami, M. McClung, and D. Kiel Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group Aging (Milano) 12 2000 1 12
P.C. De Groen, D.F. Lubbe, L.J. Hirsch, A. Daifotis, W. Stephenson, and D. Freedholm Esophagitis associated with the use of alendronate N. Engl. J. Med. 335 1996 1016 1021
B. Ettinger, A. Pressmen, and J. Schein Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation J. Manag. Care Pharm. 4 1998 488 492
F.L. Lanza, R.H. Hunt, A.B. Thomson, J.M. Provenza, and J.A. Blank Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women Gastroenterology 119 2000 631 638
R. Eastell, P. Garnero, L. Vrijens, L. van de Langerijt, H.A.P. Pols, and J.D. Ringe Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study Calcif. Tissue Int. 72 2003 408 [Abstract P-297]
R.J. Sebaldt, L.G. Shane, B. Pham, R. Cook, L. Thabane, and A. Petrie Longer-term effectiveness outcomes of non-compliance and non-persistence with daily-regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care Osteoporos. Int. 15 Suppl. 1 2004 S107 [Abstract P391SA]
E. Siris, C.J. Rosen, S.T. Harris, T. Abbott, C.E. Barr, and S. Silverman Adherence rates to bisphosphonate therapy: relationship to bone fractures at 24 months in women with postmenopausal osteoporosis Poster presented at NOF Sixth international symposium on osteoporosis 2005 [7 April]
Surgeon General. 2004. Bone health and osteoporosis: a report of the Surgeon General. http://www.hhs.gov/surgeongeneral/library/bonehealth/content. html. Accessed 10 August, 2005.
R. Bartl, S. Goette, P. Hadji, and T. Hammerschmidt Persistence and compliance with daily and weekly-administered bisphosphonates for osteoporosis treatment in Germany Osteoporos. Int. 16 Suppl. 3 2005 S45 [Abstract P195]
M.P. Ettinger, R. Gallagher, M. Amonkar, P.M. Mahoney, and J. Gilbride Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate Arthritis Rheum. 50 2004 S513 [Suppl.; Abstract 1325]
J.A. Cramer, M.M. Amonkar, A. Hebborn, and N. Suppapanya Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women? J. Bone Miner. Res. 19 Suppl. 1 2004 S448 [Abstract M434]
D. Kendler, A.W. Kung, G.-H. Fuleihan, J.G. Gonzalez-Gonzalez, K.A. Gaines, and M. Verbruggen Patients with osteoporosis prefer once weekly to once daily dosing with alendronate Maturitas 48 2004 243 251
J.A. Simon, E.M. Lewiecki, M.E. Smith, R.A. Petruschke, L. Wang, and J.J. Palmissano Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg; a multicenter, randomized, open-label, crossover study Clin. Ther. 24 2002 1871 1886
J. Simon, K.M. Beusterien, N. Kline Leidy, and A. Hebborn Women with postmenopausal osteoporosis express a preference for once-monthly versus once-weekly bisphosphonate treatment Female Patient 30 2005 31 36
R. Emkey, N. Binkley, L. Seidman, and C. Rosen BALTO I: women treated for osteoporosis rate preference and convenience for once-monthly ibandronate versus once-weekly alendronate J. Bone Miner. Res. 20 Suppl. 1 2005 S416 [Abstract M435]